SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 12th, 2021 • Compugen LTD • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 10, 2021, between Compugen Ltd., a corporation organized under the laws of the State of Israel (the “Company”), and Bristol-Myers Squibb Company (the “Purchaser”), a Delaware corporation.
Amendment No. 3 to Master Clinical Trial Collaboration AgreementTrial Collaboration Agreement • November 12th, 2021 • Compugen LTD • Biological products, (no disgnostic substances)
This Amendment No. 3 to Master Clinical Trial Collaboration Agreement (this “Amendment No. 3”) is effective as of November 10, 2021 (“Amendment No. 3 Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
